• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Metagenomi Therapeutics, Inc. - Common Stock (NQ:MGX)

    1.214 -0.006 (-0.49%)
    Streaming Delayed Price Updated: 12:32 PM EDT, Jul 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 63,663
    Open 1.210
    Bid (Size) 1.210 (35,000)
    Ask (Size) 1.220 (1,200)
    Prev. Close 1.220
    Today's Range 1.200 - 1.220
    52wk Range 1.130 - 3.950
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
    Appointments strengthen financial and scientific leadership to help advance multiple ultra-long-acting incretin and non-incretin therapies toward the clinic 
    From ProLynx Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
    From Metagenomi Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -27.3%
    -27.3%
    1 Month
    +2.0%
    +2.0%
    3 Month
    -12.0%
    -12.0%
    6 Month
    -23.2%
    -23.2%
    1 Year
    -46.5%
    -46.5%

    More News

    Read More
    News headline image
    Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
    From Metagenomi Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
    From Metagenomi Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi to Present at Jefferies Global Healthcare Conference in London
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    These stocks are moving in today's after hours session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Inc (NASDAQ:MGX) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected ↗
    Via Chartmill
    News headline image
    Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are gapping on Wednesday? ↗
    Via Chartmill
    News headline image
    Sam Altman Says He 'Didn't Think' Elon Musk Would Abuse Government Power, Tesla CEO Hits Back With 'Scam Altman' Jibe ↗
    Via Benzinga
    News headline image
    Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗
    Via Benzinga
    News headline image
    Demystifying Metagenomi: Insights From 4 Analyst Reviews ↗
    Via Benzinga
    News headline image
    Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗
    Via Benzinga
    News headline image
    Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
    From Metagenomi, Inc.
    Via GlobeNewswire
    News headline image
    Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
    From Metagenomi, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Metagenomi Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Metagenomi Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Metagenomi Therapeutics, Inc. - Common Stock trade on?
    Metagenomi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Metagenomi Therapeutics, Inc. - Common Stock?
    The ticker symbol for Metagenomi Therapeutics, Inc. - Common Stock is MGX on the Nasdaq Stock Market
    What is the current price of Metagenomi Therapeutics, Inc. - Common Stock?
    The current price of Metagenomi Therapeutics, Inc. - Common Stock is 1.214
    When was Metagenomi Therapeutics, Inc. - Common Stock last traded?
    The last trade of Metagenomi Therapeutics, Inc. - Common Stock was at 07/31/26 12:32 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.